Promethean BioPharma raises $2.3M to bring CBD pain tablet to pharmacy shelves
What's the deal? Sydney-based biotech Promethean BioPharmaDealroom has a profile for this one. Try Dealroom → has opened a US$2.07M (roughly $2.3 million) equity crowdfunding campaign on OnMarketDealroom has a profile for this one. Try Dealroom →. The raise comes as it seeks to make Australia the first country to register an over-the-counter CBD tablet for pain relief.
Why now? Promethean has lodged its zero-THC nano-particle cannabidiol tablet with the Therapeutic Goods Administration under the Provisional Registration Pathway. A decision is expected within about six months.
What's the endgame? If approved, the tablet would move from prescription-only to pharmacy shelves, reaching more than 40,000 Australian general practitioners without the Special Access Scheme or Authorised Prescriber pathways that currently govern medicinal cannabis. The funds are earmarked for manufacturing scale-up, regulatory costs, facility upgrades, physician engagement, and early-stage trials for sleep and anxiety formulations.
What could go wrong? Promethean's trial enrolled 155 adults over eight weeks and was built primarily to prove safety. It did not achieve statistically significant efficacy across the full cohort, though about 10% of patients on the active tablet were "high responders," recording a two-to-four point pain reduction on the Brief Pain Inventory Short Form.
The company's view: "We set out to prove this tablet was safe, and it is," says chief executive officer Peter Comerford. "No toxicity, no red flags, and it held up even in patients who already had heart rhythm risk factors going in."
Promethean says its proprietary delivery system enables consistent dosing and shelf stability exceeding three years, a technical hurdle that has historically slowed CBD commercialisation.
The signal: Promethean argues Australia holds a genuine head start, because the US requires its own domestic trial data before recognising overseas results, a process that typically adds at least two years. It concedes the lead is not guaranteed, warning US competitors "have the runway to close the gap and take the lead in an export category worth billions."
Read more: businessnewsaustralia.com
Image credit: Ivan Radic
